Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Therapeutic Advances in Respiratory Disease|March 19, 2024
Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysisVishal Bali, Jonathan Schelfhout, Mandel R Sher, et al.Journal of Clinical Medicine|August 10, 2024
Characteristics of US Medicare Beneficiaries with Chronic Cough vs. Non-Chronic Cough: 2011-2018Seonkyeong Yang, Shu Huang, Juan M Hincapie-Castillo, et al.The European Respiratory Journal|January 18, 2020
Gefapixant in two randomised dose-escalation studies in chronic coughJaclyn A Smith, Michael M Kitt, Peter Butera, et al.Journal of Clinical Medicine|October 14, 2023
Patterns of Cough Medication Prescribing among Patients with Chronic Cough in Florida: 2012-2021Seonkyeong Yang, Shu Huang, Juan M Hincapie-Castillo, et al.Therapeutic Advances in Respiratory Disease|September 5, 2024
Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview studyAllison Martin Nguyen, Carmen La Rosa, Alexandra G Cornell, et al.Journal of Clinical Medicine|July 9, 2022
Evaluation of Cough Medication Use Patterns in Ambulatory Care Settings in the United States: 2003-2018Seonkyeong Yang, Juan M Hincapie-Castillo, Xuehua Ke, et al.Lung|April 7, 2021
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist GefapixantAlyn H Morice, Surinder S Birring, Jaclyn A Smith, et al.Lung|June 1, 2023
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI StudyPeter V Dicpinigaitis, Alyn H Morice, Jaclyn A Smith, et al.The Lancet. Respiratory Medicine|February 29, 2020
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialJaclyn A Smith, Michael M Kitt, Alyn H Morice, et al.Pageof 1